Rationale and design of the Aortic Valve replAcemenT versus
conservative treatment in Asymptomatic seveRe aortic stenosis
(AVATAR trial): A randomized multicenter controlled
event-driven trial

J 2016

Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial

BANOVIC, Marko; Bernard IUNG; Jozef BARTUNEK; Milika ASANIN; Branko BELESLIN et al.

Základní údaje

Originální název

Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial

Autoři

Vydání

American Heart Journal, New York, Mosby Inc. 2016, 0002-8703

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.436

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00092677

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

VALVULAR HEART-DISEASE; BEFORE-SYMPTOM-ONSET; HIGH-RISK PATIENTS; NATURAL-HISTORY; CLINICAL-TRIALS; FOLLOW-UP; SURGERY; PATIENT; PROSTHESIS; SURVIVAL

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 1. 2017 11:10, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Aortic valve replacement (AVR) therapy is an obvious choice for symptomatic severe aortic stenosis (AS) patients as it improves symptoms, left ventricular function, and survival. The treatment decisions and indication for AVR in asymptomatic patients with severe AS and normal left ventricular ejection fraction are less well established and the subject of ongoing debate. Many efforts have been made to define the best treatment option in asymptomatic AS patients with normal left ventricular ejection fraction. Retrospective and observational data imply that elective AVR for asymptomatic severe AS may lead to improvement in outcomes in comparison to surgery performed after onset of symptoms. The AVATAR trial will aim to assess outcomes among asymptomatic AS patients randomized to either elective early AVR or medical management with vigilant follow-up. In the latter group, AVR would be delayed until either the onset of symptoms or changes in predefined echocardiographic parameters. To the best of the authors' knowledge, it will be the first large prospective, randomized, controlled, multicenter clinical trial that will evaluate the safety and efficacy of elective AVR in this specific group of patients.

Citovat

BANOVIC, Marko; Bernard IUNG; Jozef BARTUNEK; Milika ASANIN; Branko BELESLIN; Bojan BIOCINA; Filip CASSELMAN; Mark da COSTA; Marek DEJA; Hrvoje GASPAROVIC; Petr KALA; Lois LABROUSSE; Zlatibor LONCAR; Jelena MARINKOVIC; Ivana NEDELJKOVIC; Milan NEDELJKOVIC; Peter NEMEC; Serge D. NIKOLIC; Michael PENCINA; Martin PENICKA; Arsen RISTIC; Faidal SHARIF; Guy Van CAMP; Marc VANDERHEYDEN; Wojtek WOJAKOWSKI a Svetozar PUTNIK. Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial. American Heart Journal. New York: Mosby Inc., 2016, roč. 174, "neuvedeno", s. 147-153. ISSN 0002-8703. Dostupné z: https://doi.org/10.1016/j.ahj.2016.02.001.

@article{1366699,
   author = {Banovic, Marko and Iung, Bernard and Bartunek, Jozef and Asanin, Milika and Beleslin, Branko and Biocina, Bojan and Casselman, Filip and Costa, Mark da and Deja, Marek and Gasparovic, Hrvoje and Kala, Petr and Labrousse, Lois and Loncar, Zlatibor and Marinkovic, Jelena and Nedeljkovic, Ivana and Nedeljkovic, Milan and Nemec, Peter and Nikolic, Serge D. and Pencina, Michael and Penicka, Martin and Ristic, Arsen and Sharif, Faidal and Camp, Guy Van and Vanderheyden, Marc and Wojakowski, Wojtek and Putnik, Svetozar},
   article_location = {New York},
   article_number = {"neuvedeno"},
   doi = {https://doi.org/10.1016/j.ahj.2016.02.001},
   keywords = {VALVULAR HEART-DISEASE; BEFORE-SYMPTOM-ONSET; HIGH-RISK PATIENTS; NATURAL-HISTORY; CLINICAL-TRIALS; FOLLOW-UP; SURGERY; PATIENT; PROSTHESIS; SURVIVAL},
   language = {eng},
   issn = {0002-8703},
   journal = {American Heart Journal},
   title = {Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial},
   volume = {174},
   year = {2016}
}

TY  - JOUR
ID  - 1366699
AU  - Banovic, Marko - Iung, Bernard - Bartunek, Jozef - Asanin, Milika - Beleslin, Branko - Biocina, Bojan - Casselman, Filip - Costa, Mark da - Deja, Marek - Gasparovic, Hrvoje - Kala, Petr - Labrousse, Lois - Loncar, Zlatibor - Marinkovic, Jelena - Nedeljkovic, Ivana - Nedeljkovic, Milan - Nemec, Peter - Nikolic, Serge D. - Pencina, Michael - Penicka, Martin - Ristic, Arsen - Sharif, Faidal - Camp, Guy Van - Vanderheyden, Marc - Wojakowski, Wojtek - Putnik, Svetozar
PY  - 2016
TI  - Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial
JF  - American Heart Journal
VL  - 174
IS  - "neuvedeno"
SP  - 147-153
EP  - 147-153
PB  - Mosby Inc.
SN  - 00028703
KW  - VALVULAR HEART-DISEASE
KW  - BEFORE-SYMPTOM-ONSET
KW  - HIGH-RISK PATIENTS
KW  - NATURAL-HISTORY
KW  - CLINICAL-TRIALS
KW  - FOLLOW-UP
KW  - SURGERY
KW  - PATIENT
KW  - PROSTHESIS
KW  - SURVIVAL
N2  - Aortic valve replacement (AVR) therapy is an obvious choice for symptomatic severe aortic stenosis (AS) patients as it improves symptoms, left ventricular function, and survival. The treatment decisions and indication for AVR in asymptomatic patients with severe AS and normal left ventricular ejection fraction are less well established and the subject of ongoing debate. Many efforts have been made to define the best treatment option in asymptomatic AS patients with normal left ventricular ejection fraction. Retrospective and observational data imply that elective AVR for asymptomatic severe AS may lead to improvement in outcomes in comparison to surgery performed after onset of symptoms. The AVATAR trial will aim to assess outcomes among asymptomatic AS patients randomized to either elective early AVR or medical management with vigilant follow-up. In the latter group, AVR would be delayed until either the onset of symptoms or changes in predefined echocardiographic parameters. To the best of the authors' knowledge, it will be the first large prospective, randomized, controlled, multicenter clinical trial that will evaluate the safety and efficacy of elective AVR in this specific group of patients.
ER  -

BANOVIC, Marko; Bernard IUNG; Jozef BARTUNEK; Milika ASANIN; Branko BELESLIN; Bojan BIOCINA; Filip CASSELMAN; Mark da COSTA; Marek DEJA; Hrvoje GASPAROVIC; Petr KALA; Lois LABROUSSE; Zlatibor LONCAR; Jelena MARINKOVIC; Ivana NEDELJKOVIC; Milan NEDELJKOVIC; Peter NEMEC; Serge D. NIKOLIC; Michael PENCINA; Martin PENICKA; Arsen RISTIC; Faidal SHARIF; Guy Van CAMP; Marc VANDERHEYDEN; Wojtek WOJAKOWSKI a Svetozar PUTNIK. Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial. \textit{American Heart Journal}. New York: Mosby Inc., 2016, roč.~174, ''neuvedeno'', s.~147-153. ISSN~0002-8703. Dostupné z: https://doi.org/10.1016/j.ahj.2016.02.001.

Přehled o publikaci